Corporate ActionJun 18, 2026, 05:17 PM
Sensei Biotherapeutics Launches $150M ATM Stock Offering
AI Summary
Sensei Biotherapeutics, Inc. has entered into a Sales Agreement with TD Securities (USA) LLC to establish an At-The-Market (ATM) offering program. This program allows the company to sell shares of its common stock with an aggregate offering price of up to $150,000,000. Additionally, 24,435.594 shares of Series B Non-Voting Convertible Preferred Stock automatically converted into an equal number of common shares, increasing the total outstanding common stock to 25,778,754 shares as of June 15, 2026.
Key Highlights
- Sensei Biotherapeutics entered into a Sales Agreement with TD Securities (USA) LLC for an At-The-Market (ATM) offering.
- The company may offer and sell common stock with an aggregate offering price of up to $150,000,000.
- TD Securities will receive a commission of up to 3.0% of the aggregate gross sales price per share.
- On June 15, 2026, 24,435.594 shares of Series B Non-Voting Convertible Preferred Stock converted into 24,435,594 common shares.
- As a result, Sensei Biotherapeutics now has 25,778,754 shares of Common Stock outstanding as of June 15, 2026.
Price Impact
More from SNSE